Drugs / Autologous Platelet-Rich Plasma (PRP)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05525572 | Feb → Aug 2024 | erectile dysfunction | University of Miami | Terminated | No outcome recorded Stop: Business |
| Phase not applicable1 trial | ||||||
| — | NCT07669285 | Jun 2026 overdue | obstetric disorder | Saint Andrew Hospital Constanta | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Platelet-Rich Plasma (PRP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07669285 ↗ |
| Known as | PRP | “Biological: Autologous Platelet-Rich Plasma (PRP)” NCT07669285 ↗ |
| Route | Other | “The resulting PRP is administered as a single local injection into the tissue at the margins and base of the episiotomy wound, performed intraoperatively or immediately...” NCT07669285 ↗ |